Patent Grant

RNS Number:1634Q
Lipoxen PLC
17 March 2008



Lipoxen reports further advancement of its DNA vaccine delivery patent portfolio

          US allows further patent for Lipoxen's ImuXen(R) technology


London, UK, 17th March 2008 - Lipoxen PLC, (AIM:LPX) a bio-pharmaceutical
company specialising in the development of high value differentiated
biologicals, vaccines and oncology drugs, announces today that an important
ImuXen(R) patent (No 10/149670) has been allowed in the US, following grant in
Europe in 2004. This extension of Lipoxen's DNA vaccine delivery patent estate
covers its capisome technology, which relates to the entrapment of DNA vaccines
into liposomes made of uncharged lipids rather than cationic (positively
charged) liposomes.

In the capisome approach, DNA is complexed with calcium and then trapped into
neutral liposomes. Recognising the need for a new delivery system as, although
harmless if used over a few injections, cationic lipids can present problems on
prolonged use, Lipoxen developed a technology that could be applied chronically,
and is viewed as essential for a more widespread use for DNA therapy.

A further advantage of the capisome approach is that the delivery method is not
limited to DNA vaccines, and it has the potential to be used in gene therapy and
other nucleic acid-based therapies such as siRNA. Other benefits are expected to
include low toxicity and capability to carry large amounts of DNA. The
technology can also be applied in conjunction with Lipoxen's current ImuXen
co-delivery approach, in which DNA vaccines and the proteins they encode are
delivered together in order to provide an enhanced immune response.

The allowance of this patent comes shortly after one of Lipoxen's cornerstone
ImuXen patents (No 10/617734), which covers the encapsulation of DNA inside a
liposome, was allowed in the US. Both these approaches further protect Lipoxen's
position in the field of DNA vaccine delivery technology and help ensure that
its advanced ImuXen technology continues to be at the forefront of novel vaccine
development.


M. Scott Maguire, CEO of Lipoxen, said:

"Realising that a strong intellectual property position is key to our future
success, the allowance of this patent in the US further strengthens our position
as a leader in the development of DNA delivery technology with ImuXen. The
potential widespread use of the capisome technology beyond vaccines into
delivery of other DNA-based medicines increases the value of our patent estate,
and we expect it to play a key role in the generation of further deals and R&D
collaborations."


                                      Ends

Enquiries

Lipoxen PLC
M. Scott Maguire, Chief Executive Officer             [phone]

Landsbanki Securities (UK) Limited (nominated
adviser)
Shaun Dobson / Claes Spang                            [phone]

Citigate Dewe Rogerson                                [phone]
David Dible / Emma Palmer



Notes to Editors

Lipoxen PLC (AIM:LPX) is a biopharmaceutical company specializing in the
development of high value differentiated biologicals, vaccines and oncology
drugs. Products currently under development include improved formulations of
important biologicals such as erythropoietin (EPO), G-CSF, insulin and
Interferon-alpha. Lipoxen has two products in clinical development SuliXen, a
long acting insulin and long-acting EPO. These novel products, which are based
on Lipoxen's proprietary PolyXen(R) technology, each address markets in excess
of US$1 billion.

Lipoxen's technology is designed to improve the stability, biological half-life
and immunologic characteristics of therapeutic proteins naturally. Lipoxen has
two further naturally-derived proprietary delivery technologies, ImuXen(R) and a
related liposomal technology for the formulation of cytotoxic oncology drugs,
which are being developed to enhance the efficacy and safety of various vaccines
such as a multivalent Hepatitis B-E and pneumococcal vaccines, as well as a
number of anti-cancer agents like paclitaxel. The Company's proprietary delivery
technologies are attracting significant interest and Lipoxen is currently
co-developing products with the Serum Institute of India Limited (one of the
world's leading vaccine companies, India's largest biotech company and a major
shareholder in Lipoxen) and has license agreements in place with Baxter
International and InterVet, a leading animal health company.

Lipoxen was admitted to trading on the AIM Market of the London Stock Exchange
in January 2006.

This announcement includes 'forward-looking statements' which include all
statements other than statements of historical facts, including, without
limitation, those regarding the Company's financial position, business strategy,
plans and objectives of management for future operations (including development
plans and objectives relating to the Company's products and services), and any
statements preceded by, followed by or that include forward-looking terminology
such as the words 'targets', 'believes', 'estimates', 'expects', 'aims',
'intends', 'will', 'can', 'may', 'anticipates', 'would', 'should', 'could' or
similar expressions or the negative thereof. Such forward-looking statements
involve known and unknown risks, uncertainties and other important factors
beyond the Company's control that could cause the actual results, performance or
achievements of the Company to be materially different from future results,
performance or achievements expressed or implied by such forward-looking
statements. Such forward-looking statements are based on numerous assumptions
regarding the Company's present and future business strategies and the
environment in which the Company will operate in the future. Among the important
factors that could cause the Company's actual results, performance or
achievements to differ materially from those in forward-looking statements
include those relating to The Company's funding requirements, regulatory
approvals, clinical trials, reliance on third parties, intellectual property,
key personnel and other factors. These forward-looking statements speak only as
at the date of this announcement. The Company expressly disclaims any obligation
or undertaking to disseminate any updates or revisions to any forward-looking
statements contained in this announcement  to reflect any change in the
Company's expectations with regard thereto or any change in events, conditions
or circumstances on which any such statements are based. As a result of these
factors, readers are cautioned not to rely on any forward-looking statement.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCSFAFLLSASEDD